company background image
A298380 logo

ABL Bio KOSDAQ:A298380 Stock Report

Last Price

₩62.20k

Market Cap

₩2.7t

7D

40.6%

1Y

179.6%

Updated

14 Apr, 2025

Data

Company Financials +

A298380 Stock Overview

A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. More details

A298380 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

ABL Bio Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ABL Bio
Historical stock prices
Current Share Price₩62,200.00
52 Week High₩58,800.00
52 Week Low₩21,200.00
Beta1.02
1 Month Change65.21%
3 Month Change101.29%
1 Year Change179.55%
3 Year Change148.80%
5 Year Change243.65%
Change since IPO355.68%

Recent News & Updates

ABL Bio (KOSDAQ:298380) Has Debt But No Earnings; Should You Worry?

Mar 26
ABL Bio (KOSDAQ:298380) Has Debt But No Earnings; Should You Worry?

Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Nov 20
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Recent updates

ABL Bio (KOSDAQ:298380) Has Debt But No Earnings; Should You Worry?

Mar 26
ABL Bio (KOSDAQ:298380) Has Debt But No Earnings; Should You Worry?

Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Nov 20
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?

May 29
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?

Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?

Feb 26
Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?

We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Mar 31
We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

Jan 20
Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Dec 16
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Shareholder Returns

A298380KR BiotechsKR Market
7D40.6%-0.2%-1.0%
1Y179.6%16.7%-11.5%

Return vs Industry: A298380 exceeded the KR Biotechs industry which returned 16.7% over the past year.

Return vs Market: A298380 exceeded the KR Market which returned -11.5% over the past year.

Price Volatility

Is A298380's price volatile compared to industry and market?
A298380 volatility
A298380 Average Weekly Movement14.7%
Biotechs Industry Average Movement7.1%
Market Average Movement6.1%
10% most volatile stocks in KR Market12.5%
10% least volatile stocks in KR Market2.8%

Stable Share Price: A298380's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A298380's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSang Hoon Leewww.ablbio.com

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.

ABL Bio Inc. Fundamentals Summary

How do ABL Bio's earnings and revenue compare to its market cap?
A298380 fundamental statistics
Market cap₩2.73t
Earnings (TTM)-₩55.53b
Revenue (TTM)₩33.40b

90.4x

P/S Ratio

-54.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A298380 income statement (TTM)
Revenue₩33.40b
Cost of Revenue₩61.26m
Gross Profit₩33.34b
Other Expenses₩88.87b
Earnings-₩55.53b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.14k
Gross Margin99.82%
Net Profit Margin-166.24%
Debt/Equity Ratio25.7%

How did A298380 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/14 09:55
End of Day Share Price 2025/04/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABL Bio Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Haesoon KwonEugene Investment & Securities Co Ltd.
Jihoon ShinLS Securities Co., Ltd.